Results 141 to 150 of about 19,986 (197)
Some of the next articles are maybe not open access.
Hypolipidemic arylthioalkanoic acids
Journal of Medicinal Chemistry, 1977A series of arylthioalkanoic acids related to probucol was studied for hypolipidemic activity. Homologation of the alkyl side chain led to marked changes in the serum cholesterol and serum triglyceride lowering activity in rats with the best combination of properties appearing in compound 7, 2-[3,5-di-tert-butyl-4-hydroxyphenyl)thio]hexanoic acid ...
E R, Wagner +7 more
openaire +2 more sources
Hepatotoxicity of hypolipidemic drugs
Clinics in Liver Disease, 2003Dyslipidemic conditions and their cardiovascular related complications are common. Effective primary and secondary prevention strategies include therapies to lower LDL and total cholesterol and to increase HDL. Further, it seems that there is a need for therapeutic reduction in triglycerides as it emerges as an independent risk factor for CVD.
Javier L, Parra, K Rajender, Reddy
openaire +2 more sources
Hypolipidemic activity of rifamycin derivatives
Journal of Medicinal Chemistry, 1990Series of 3-piperidinyl- and 3-piperazinylrifamycins and to a certain extent 3-hydrazonorifamycins all bearing lipophilic side chains were found to exert potent hypolipidemic activity in lowering both serum cholesterol and LDL-cholesterol in rats.
P, Traxler +3 more
openaire +2 more sources
1978
The past 12 months have been an encouraging period for the development of new hypolipidemic agents. The Food and Drug Administration approved the drugs Probucol from Dow Chemical Company and Colestipol-HCl from Upjohn Company as official hypolipidemic agents.
openaire +2 more sources
The past 12 months have been an encouraging period for the development of new hypolipidemic agents. The Food and Drug Administration approved the drugs Probucol from Dow Chemical Company and Colestipol-HCl from Upjohn Company as official hypolipidemic agents.
openaire +2 more sources
1975
The inhibition of lipidemia can be achieved in several ways. The most logical mechanism — interference with lipoprotein metabolism (synthesis, release or catabolism) — has not been approached in a rational manner. There are some effective hypolipidemic drugs but their mechanisms of action are not clear and the search for a more effective compound ...
openaire +2 more sources
The inhibition of lipidemia can be achieved in several ways. The most logical mechanism — interference with lipoprotein metabolism (synthesis, release or catabolism) — has not been approached in a rational manner. There are some effective hypolipidemic drugs but their mechanisms of action are not clear and the search for a more effective compound ...
openaire +2 more sources
The Current Status of Hypolipidemic Drugs
Postgraduate Medicine, 1970Dietary counseling is recommended as the first step in management of the patient with an abnormally high plasma cholesterol or triglyceride level. If diet alone does not bring about a satisfactory reduction, addition of a lipid-lowering drug should be considered.
R I, Levy, D S, Fredrickson
openaire +2 more sources
Hypolipidemic therapy and cholesterol absorption
Current Atherosclerosis Reports, 2004The advent of safe and effective hypolipidemic therapy has revolutionized the ability of the clinician to optimize abnormalities in the lipid profile. The advent of statin therapy has provided a potent option to decrease low-density lipoprotein and frequently allows achievement of National Cholesterol Education Program target lipid levels with ...
Amit, Manhas, John A, Farmer
openaire +2 more sources
Mechanisms of the Hypolipidemic Action of Fibrates
1998Fibrates are generally effective in lowering elevated plasma triglycerides and cholesterol. The magnitude of lipid changes depends however upon the patients’ pretreatment lipoprotein status [1],as well as upon the unique properties of each fibrate. The most pronounced effects of fibrates are a decrease in plasma triglyceride-rich lipoproteins and an ...
Auwerx, J. +4 more
openaire +2 more sources
Hypolipidemic therapy for the metabolic syndrome
Pharmacological Research, 2006The metabolic syndrome appears to affect a significant proportion of the population and is associated with increased risk for development of cardiovascular disease as well as of type-2 diabetes. No single treatment for the metabolic syndrome as a whole yet exists.
CIGNARELLA, ANDREA +3 more
openaire +2 more sources
Journal of Medicinal Chemistry, 1980
More than 110 derivatives of alkoxycinnamic acids were synthesized and their hypolipidemic activities were evaluated in a screening system with rats. Cinnamic acids, alpha-methylcinnamic acids, and their various esters with a higher p-alkoxy substituent were found to possess hypolipidemic activities higher than or comparable to that of clofibrate.
T, Watanabe +5 more
openaire +2 more sources
More than 110 derivatives of alkoxycinnamic acids were synthesized and their hypolipidemic activities were evaluated in a screening system with rats. Cinnamic acids, alpha-methylcinnamic acids, and their various esters with a higher p-alkoxy substituent were found to possess hypolipidemic activities higher than or comparable to that of clofibrate.
T, Watanabe +5 more
openaire +2 more sources